Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824824 · ClinicalTrials.gov registry record · NA
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
A NA study of Glaucoma, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00824824 is a NA study of Glaucoma that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 21 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00824824, a NA study of Glaucoma, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by dilating and constricting in order to maintain a steady blood flow rate. In an eye with POAG, this often does not occur. As a result, there are large fluctuations in blood flow which may produce the retinal neuronal damage associated with glaucoma. The purpose of this study is to demonstrate that topical anti-glaucoma treatments with agents that have vasoactive as well as IOP-lowering effects can have a beneficial effect on maintaining a steady retinal blood flow rate even when there are changes in local blood pressure.
Conditions Studied
Interventions
- DRUG Dorzolamide 2%-timolol 0.5%
- DRUG Brimonidine 0.2%-0.5% timolol 0.5
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824824
The ClinicalTrials.gov registry entry for NCT00824824 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Dorzolamide 2%-timolol 0.5% is the first listed.
NCT00824824 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00824824 about?
NCT00824824 is a clinical study titled "Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)". We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vascula...
What is the current status of trial NCT00824824?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2009-01. Estimated completion is 2012-08.
What conditions does trial NCT00824824 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00824824?
The interventions under investigation include: Dorzolamide 2%-timolol 0.5% (DRUG), Brimonidine 0.2%-0.5% timolol 0.5 (DRUG).
Who is sponsoring clinical trial NCT00824824?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00824824 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.